^
    Back
    Association details:
    Biomarker:FOLR1 expression
    Cancer:Endometrial Cancer
    Drug:rinatabart sesutecan (PRO1184) (Topoisomerase I inhibitor, Folate receptor 1-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    PRO1184 for Advanced Solid Tumors

    Excerpt:
    ...- for Part B, evidence of folate receptor alpha expression in tumor cells...
    Trial ID:
    PRO1184-001
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2023
    Title:

    708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

    Published date:
    11/04/2023
    Excerpt:
    Antitumor activity was observed at both dose levels and in patients with high, medium, and low FRα expression, including an ongoing confirmed partial response in a patient with endometrial cancer and decreased tumor measurements in additional patients...Antitumor activity has been observed at well tolerated dose levels.
    DOI:
    10.1136/jitc-2023-SITC2023.0708
    Trial ID:
    PRO1184-001